Wardati Mazlan-Kepli
Antiplatelet therapy following ischaemic stroke: continue or change pre-existing therapy?
Mazlan-Kepli, Wardati; MacIsaac, Rachael L.; Walters, Matthew; Bath, Philip M.W.; Dawson, Jesse
Authors
Rachael L. MacIsaac
Matthew Walters
Philip M.W. Bath
Jesse Dawson
Abstract
Introduction: Antiplatelet therapy is routinely prescribed early after ischaemic stroke. Many patients will already be taking antiplatelet therapy and it is unknown whether these patients should continue the same antiplatelet treatment or switch to a different regimen.
Methods:We selected patients with ischaemic stroke from the Virtual International Stroke Trials Archive database who were prescribed antiplatelets both before and after their stroke and who had detailed records of adverse events after stroke. We compared patients who changed to a new antiplatelet regimen after their stroke to those who continued the same regimen. The primary outcome was recurrent ischaemic stroke within 90 days after their index stroke and the secondary outcome was intracranial haemorrhage (ICH) or extracranial haemorrhage (ECH). We used logistic regression analysis and adjusted for age and baseline NIHSS.
Results: A total of 1129 participants were included. Of these, 538 subjects changed antiplatelet regimen post stroke and 591 continued the same regimen. A recurrent ischaemic event occurred in 4.1% of subjects who changed regimen and 4.3% who continued unchanged (adjusted OR¼0.93; 95% CI 0.54–1.75, p¼0.929). The incidence of ICH and ECH within the first 90 days was similar in both groups (2.4% vs. 2.6% (adjusted OR¼1.02; 95% CI 0.48–2.18, p¼0.955) and 4.7% vs. 2.9% (adjusted OR¼1.82; 95% CI 0.96–3.43, p¼0.065), respectively).
Discussion: The analysis was performed using a non-randomised registry data.
Conclusion: In patients who suffer ischaemic stroke whilst taking antiplatelets, a change in antiplatelet regimen was not associated with an altered risk of early recurrent ischaemic stroke rate or bleeding. However, the results must be interpreted in view of the low event rates.
Citation
Mazlan-Kepli, W., MacIsaac, R. L., Walters, M., Bath, P. M., & Dawson, J. (2017). Antiplatelet therapy following ischaemic stroke: continue or change pre-existing therapy?. European Stroke Journal, 2(1), https://doi.org/10.1177/2396987316678728
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 19, 2016 |
Online Publication Date | Nov 4, 2016 |
Publication Date | Mar 1, 2017 |
Deposit Date | Aug 16, 2017 |
Publicly Available Date | Mar 29, 2024 |
Journal | European Stroke Journal |
Electronic ISSN | 2396-9873 |
Publisher | SAGE Publications |
Peer Reviewed | Peer Reviewed |
Volume | 2 |
Issue | 1 |
DOI | https://doi.org/10.1177/2396987316678728 |
Keywords | Antiplatelet, recurrent ischaemic stroke, intracranial haemorrhage, outcomes, thrombolysis, prior antiplatelet |
Public URL | https://nottingham-repository.worktribe.com/output/843065 |
Publisher URL | http://journals.sagepub.com/doi/10.1177/2396987316678728 |
Files
ACCEPTED MANUSCRIPT - Antiplatelet therapy following ischaemic stroke.pdf
(118 Kb)
PDF
You might also like
Key design elements of successful acute ischemic stroke treatment trials
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search